Armodafinil

Armodafinil (Nuvigil®) is an eugeroic drug produced by the pharmaceutical company Cephalon Inc., currently in the process of receiving Food and Drug Administration (FDA) approval. Armodafinil is the r-enantiomer of modafinil, so is expected to act in a similar manner, with similar effects. However, it acts for a longer duration of time than modafinil. Cephalon hopes to soon release the longer-lasting Nuvigil (R-modafinil) as a "truly once-a-day" wakefulness medication. In 2006, the FDA sent Cephalon an "approvable letter" for Nuvigil, pending agreement on the final product labeling. Upon approval, it is expected to be classified as a Schedule IV controlled substance.